Capital Markets Day

RNS Number : 2602N
NetScientific PLC
15 May 2015
 

 

NetScientific plc

("NetScientific" or the "Group")

 

Capital Markets Day

 

 

London, UK - 15 May 2015 - NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, is holding a Capital Markets Day for institutional investors and analysts today in London.

 

The event includes a presentation on NetScientific's refined strategy which has been under review since the full year results in March. In summary, the strategy is to fund, develop and manage early and mid-stage healthcare technology companies sourced from strategic partnerships and relationships in the USA and UK. The primary focus will remain on digital health, diagnostics and therapeutics. These sectors represent highly attractive growth markets where breakthrough technology solutions are in high demand. The Group will be concentrating on its five lead companies and further strengthening its strategic relationships with partners such as Breakout Labs, to build a unique transformative portfolio. 

There will also be presentations from key companies in the portfolio. A copy of the presentations from the day will be made available on the website:
www.netscientific.net.

No new information will be disclosed during the Capital Markets Day.

 

-Ends-

 

About NetScientific

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net. 

 

 

Contact Details

 

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDBGDURBBBGUS
UK 100

Latest directors dealings